Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC raised its holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 86.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 553,247 shares of the company’s stock after acquiring an additional 256,635 shares during the period. Geode Capital Management LLC’s holdings in Lexeo Therapeutics were worth $5,003,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Frazier Life Sciences Management L.P. acquired a new position in Lexeo Therapeutics in the third quarter valued at $11,307,000. Janus Henderson Group PLC grew its holdings in Lexeo Therapeutics by 18.9% in the 3rd quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock valued at $33,997,000 after buying an additional 599,203 shares during the period. State Street Corp grew its holdings in Lexeo Therapeutics by 29.4% in the 3rd quarter. State Street Corp now owns 253,946 shares of the company’s stock valued at $2,296,000 after buying an additional 57,674 shares during the period. Verition Fund Management LLC increased its stake in shares of Lexeo Therapeutics by 84.5% during the 3rd quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock valued at $7,027,000 after acquiring an additional 355,928 shares during the last quarter. Finally, Barclays PLC lifted its holdings in shares of Lexeo Therapeutics by 162.2% during the 3rd quarter. Barclays PLC now owns 50,210 shares of the company’s stock worth $454,000 after acquiring an additional 31,057 shares during the period. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Insider Transactions at Lexeo Therapeutics

In other news, CEO Richard Nolan Townsend sold 5,000 shares of the business’s stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $8.10, for a total transaction of $40,500.00. Following the transaction, the chief executive officer now directly owns 120,695 shares of the company’s stock, valued at approximately $977,629.50. The trade was a 3.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 10,000 shares of company stock valued at $80,550 over the last quarter. Company insiders own 4.50% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on LXEO. Chardan Capital upped their price target on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Leerink Partners dropped their price objective on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Wednesday, November 13th. Finally, HC Wainwright lifted their target price on Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Lexeo Therapeutics presently has a consensus rating of “Buy” and an average price target of $23.80.

Lexeo Therapeutics Stock Up 9.3 %

Shares of Lexeo Therapeutics stock opened at $7.29 on Friday. Lexeo Therapeutics, Inc. has a twelve month low of $5.77 and a twelve month high of $22.33. The stock has a market cap of $241.05 million and a price-to-earnings ratio of -2.31. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average price of $7.31 and a 200 day moving average price of $10.21.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.